High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer

INTRODUCTION: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer with poor prognosis and resistance to hormone therapy, which has limited therapeutic approaches. Therefore, this study aimed to identify a novel treatment for NEPC and provide evidence of its inhibitory e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei, Ji, Yiyi, Li, Ang, Liu, Bo, Shen, Kai, Su, Ruopeng, Ma, Zehua, Zhang, Weiwei, Wang, Qi, Zhu, Yinjie, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042075/
https://www.ncbi.nlm.nih.gov/pubmed/36994207
http://dx.doi.org/10.3389/fonc.2023.1085569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042075/
https://www.ncbi.nlm.nih.gov/pubmed/36994207
http://dx.doi.org/10.3389/fonc.2023.1085569

Ejemplares similares